Breaking News, Collaborations & Alliances

Zydus & Formycon Partner for Keytruda Biosimilar in US & Canada

Formycon will develop, register, manufacture, and supply the product, while Zydus will be responsible for commercialization.

By: Rachel Klemovitch

Assistant Editor

Zydus Lifesciences Limited’s wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, entered a strategic partnership with Formycon AG for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab) in the USA and Canada market. Under the terms of this agreement, Formycon AG will develop, register, manufacture, and supply the product. At the same time, Zydus Lifesciences Global FZE, United Arab Emirates, will be responsible ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters